| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Senior VP, Development
1 company
Michael David Smith last filed a Form 4 in May 2022, as Senior VP, Development at KALV. Michael David Smith's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Michael David Smith has 6 Form 4 filings on record from December 2020 to May 2022, all as Senior VP, Development at KalVista Pharmaceuticals (KALV), 2020–2022.
The 9 reported transactions were 5 option or other derivative awards, 2 option exercises and 2 open-market sales.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $459K.
The largest open-market sale was 10,014 shares of KALV at an average $25.76 on April 28, 2021, about $258K. Twelve months later KALV was down 50%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.